How to Buy Collplant Biotechnologies Stock
Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd. , a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe.
Collplant Biotechnologies stock last closed at $5.91, down 0.97% from the previous day, and has decreased 14.1% in one year. It has overperformed other stocks in the Biotechnology industry by 0.16 percentage points. Collplant Biotechnologies stock is currently +38.41% from its 52-week low of $4.27, and -57.7% from its 52-week high of $13.97.
As of Sep 25, 2023, there are 11.41M shares of CLGN outstanding. The market cap of CLGN is $67.41M. In the last 24 hours, 55,601 CLGN shares were traded.
How to Buy Collplant Biotechnologies Stock
Wondering how to invest in Collplant Biotechnologies stock? Here's how.
- Choose where to buy Collplant Biotechnologies stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you determine where to buy Collplant Biotechnologies stock.
- Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Pick your payment method and add your information.
- Evaluate Collplant Biotechnologies stock: The Collplant Biotechnologies ticker symbol is CLGN. Is Collplant Biotechnologies stock a good investment? Should you buy shares of CLGN? How do CLGN's underlying business fundamentals look? Do top analysts think Collplant Biotechnologies is a good buy? Why has CLGN's stock price moved recently? (Hint: Our stock market research website can help you decide if CLGN is a good stock to buy).
- Make your CLGN trade: Decide if you will purchase CLGN shares at the current market price or use a limit order to purchase CLGN shares at a particular price.
- Get updates on your CLGN investment: Create a watchlist to important updates regarding your new investment in Collplant Biotechnologies shares.
Step 1: Choose where to buy Collplant Biotechnologies stock
You will need an online brokerage account in order to access the NASDAQ market and buy CLGN shares.
Our preferred brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to world financial markets: From Tech to Healthcare, New York to Tokyo — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro offers a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro now.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've picked the right brokerage, you need to fill out some personal details so you are able to buy CLGN today.
How to Create a New Account on eToro
- Click here to get started.
- Input your personal info to create your new brokerage account.
- Send your data by clicking the "Create Account" button.
Step 3: Deposit funds into your brokerage account
Now that you have created your account on the best stock buying app, you can securely and quickly fund your account:
Check out the tutorial below if you need help transferring funds into your investment account.
Step 4: Evaluate Collplant Biotechnologies stock
Once you have identified the best place to buy Collplant Biotechnologies stock, it's important to evaluate their stock before you buy, so you truly understand the risk as well as the upside.
Collplant Biotechnologies shares data
CLGN Zen Score
WallStreetZen was built to help average investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on CLGN's stock page.
Is CLGN stock overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge CLGN's true value.
Using relative valuations metrics:
- CLGN could be undervalued based on its P/B ratio of 1.87x, relative to Biotechnology industry P/B ratio of 5.09x
You can do more valuation analysis on CLGN's stock here.
CLGN Financial Health
Positive Financial Indicators:
- CLGN has a low debt to equity ratio of 0.15.
- Total CLGN debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the CLGN balance sheet.
- CLGN has cash burn of 14833000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the CLGN balance sheet.
Negative Financial Indicators:
- CLGN profit margin has gone up by 25.14 percentage points in the past year, but the company is still unprofitable.
- CLGN has $22.37M in cash and short term investments. This is not enough to cover its annual cash burn of $14.83M.
Is it a good time to buy Collplant Biotechnologies stock, according to analysts?
Out of 1 Wall Street analysts who give forecasts on CLGN, the consensus analyst rating on Collplant Biotechnologies is a Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent CLGN Analyst Forecasts
Swayampakula Ramakanth, a bottom 1% analyst from HC Wainwright & Co. reiterates CLGN with a buy rating and maintains their CLGN price target from $11.00 to $11.00, on Aug 25, 2023.
You can dig deeper into what analysts are projecting on the Collplant Biotechnologies stock forecast page.
CLGN Technical Indicators
CLGN Performance Numbers
Last year, CLGN revenue was $10.78M. During the last 5 year, CLGN's revenue has grown by 70.7% per year. This was slower than the Biotechnology industry average of 108.8%.
Dig into CLGN's earnings and revenue performance here.
Who is buying/selling CLGN?
Over the last year, insiders at CLGN have not bought or sold any shares.
Learn more about who owns CLGN shares here.
Can I get consistent income from CLGN stock?
No, Collplant Biotechnologies doesn't provide an income stream by paying out dividends.
CLGN Social Trading Data
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Make your CLGN trade
You have two primary options:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are usually the best for newer investors. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at an exact dollar amount limit, place a limit order.
Press the Open Trade button and eToro will execute your order.
If you need more help buying stocks on eToro, watch the how to video below:
Step 6: Get updates on your CLGN investment
Now that you own some CLGN shares, you'll want to stay up-to-date on your new investment.
Create a watchlist to keep track of your CLGN stock.
CLGN Feed
How to Buy Stock in Collplant Biotechnologies
To reiterate, here are the 6 steps to buy stock in Collplant Biotechnologies:
- Choose where to buy Collplant Biotechnologies stock
- Sign up for a brokerage account
- Deposit funds into your brokerage account
- Evaluate Collplant Biotechnologies stock
- Make your CLGN trade
- Get updates on your CLGN investment
If you need a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to keep an eye on your new investment in Collplant Biotechnologies, add CLGN to your watchlist below.
Trending Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.